Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

This phase 2, randomized, double-blind, placebo-controlled clinical trial investigated the potential of pramlintide as a weight loss agent in obese individuals without diabetes. The study included 204 obese adults (BMI 30-50 kg/m²) who were randomized to different dose-escalation regimens of pramlintide or placebo for 16 weeks.

The study design used dose escalation to optimize gastrointestinal tolerability, which is the main dose-limiting side effect of amylin analogs. Participants received subcutaneous pramlintide before main meals, with gradual dose increases.

The results demonstrated:

• Weight loss of 3.7% beyond placebo in the best-responding group
• 31% of patients in the pramlintide group achieved weight loss ≥5% vs. only 2% on placebo
• Progressive and continuous weight reduction over 16 weeks, with no apparent plateau
• The effect was dose-dependent, suggesting potential for greater efficacy with optimized doses

The mechanism of action of pramlintide in weight loss involves activation of amylin receptors in the area postrema of the brainstem, promoting central satiety and reduced caloric intake. Unlike many anti-obesity agents, pramlintide demonstrated a favorable cardiovascular safety profile. This study was important in establishing amylin as a viable therapeutic target for obesity, regardless of the presence of diabetes.